Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 737

1.

Contractile dysfunction and nitrergic dysregulation in small intestine of a primate model of Parkinson's disease.

Coletto E, Dolan JS, Pritchard S, Gant A, Hikima A, Jackson MJ, Benham CD, Chaudhuri KR, Rose S, Jenner P, Iravani MM.

NPJ Parkinsons Dis. 2019 Jun 10;5:10. doi: 10.1038/s41531-019-0081-9. eCollection 2019.

2.

Should there be less emphasis on levodopa-induced dyskinesia in Parkinson's disease?

Chaudhuri KR, Jenner P, Antonini A.

Mov Disord. 2019 Jun;34(6):816-819. doi: 10.1002/mds.27691. Epub 2019 Apr 14. No abstract available.

PMID:
30983023
3.

The treatment of levodopa-induced dyskinesias: Surfing the serotoninergic wave.

Jenner P.

Mov Disord. 2018 Nov;33(11):1670-1672. doi: 10.1002/mds.27525. No abstract available.

PMID:
30485909
4.

Apomorphine infusion in advanced Parkinson disease.

Antonini A, Jenner P.

Nat Rev Neurol. 2018 Dec;14(12):693-694. doi: 10.1038/s41582-018-0083-y. No abstract available.

PMID:
30279608
5.

The effect of Banisteriopsis caapi (B. caapi) on the motor deficits in the MPTP-treated common marmoset model of Parkinson's disease.

Fisher R, Lincoln L, Jackson MJ, Abbate V, Jenner P, Hider R, Lees A, Rose S.

Phytother Res. 2018 Apr;32(4):678-687. doi: 10.1002/ptr.6017. Epub 2018 Jan 24.

PMID:
29368409
6.

A glimmer of light at the end of the tunnel?

Jenner P.

Mov Disord. 2017 Oct;32(10):1343-1344. doi: 10.1002/mds.27179. Epub 2017 Sep 18. No abstract available.

PMID:
28921664
7.

Nonmotor Symptoms in Experimental Models of Parkinson's Disease.

Titova N, Schapira AHV, Chaudhuri KR, Qamar MA, Katunina E, Jenner P.

Int Rev Neurobiol. 2017;133:63-89. doi: 10.1016/bs.irn.2017.05.018. Epub 2017 Jul 10. Review.

PMID:
28802936
8.

Two hundred years since James Parkinson's essay on the shaking palsy-Have we made progress? Insights from the James Parkinson's 200 years course held in London, March 2017.

Chaudhuri KR, Jenner P.

Mov Disord. 2017 Sep;32(9):1311-1315. doi: 10.1002/mds.27104. Epub 2017 Aug 11. Review. No abstract available.

PMID:
28799259
9.

Magnetic resonance imaging and tensor-based morphometry in the MPTP non-human primate model of Parkinson's disease.

Modo M, Crum WR, Gerwig M, Vernon AC, Patel P, Jackson MJ, Rose S, Jenner P, Iravani MM.

PLoS One. 2017 Jul 24;12(7):e0180733. doi: 10.1371/journal.pone.0180733. eCollection 2017.

10.

Non-oral dopaminergic therapies for Parkinson's disease: current treatments and the future.

Ray Chaudhuri K, Qamar MA, Rajah T, Loehrer P, Sauerbier A, Odin P, Jenner P.

NPJ Parkinsons Dis. 2016 Dec 1;2:16023. doi: 10.1038/npjparkd.2016.23. eCollection 2016. Review.

11.

Non-motor features of Parkinson disease.

Schapira AHV, Chaudhuri KR, Jenner P.

Nat Rev Neurosci. 2017 Aug;18(8):509. doi: 10.1038/nrn.2017.91. Epub 2017 Jul 13.

PMID:
28720825
12.

Non-motor features of Parkinson disease.

Schapira AHV, Chaudhuri KR, Jenner P.

Nat Rev Neurosci. 2017 Jul;18(7):435-450. doi: 10.1038/nrn.2017.62. Epub 2017 Jun 8. Review. Erratum in: Nat Rev Neurosci. 2017 Aug;18(8):509.

PMID:
28592904
13.

Cystatin C as a potential therapeutic mediator against Parkinson's disease via VEGF-induced angiogenesis and enhanced neuronal autophagy in neurovascular units.

Zou J, Chen Z, Wei X, Chen Z, Fu Y, Yang X, Chen D, Wang R, Jenner P, Lu JH, Li M, Zhang Z, Tang B, Jin K, Wang Q.

Cell Death Dis. 2017 Jun 1;8(6):e2854. doi: 10.1038/cddis.2017.240.

14.

New Symptomatic Treatments for the Management of Motor and Nonmotor Symptoms of Parkinson's Disease.

Taddei RN, Spinnato F, Jenner P.

Int Rev Neurobiol. 2017;132:407-452. doi: 10.1016/bs.irn.2017.03.004. Epub 2017 May 16. Review.

PMID:
28554417
15.

Hallmarks of Treatment Aspects: Parkinson's Disease Throughout Centuries Including l-Dopa.

Kim HJ, Jeon BS, Jenner P.

Int Rev Neurobiol. 2017;132:295-343. doi: 10.1016/bs.irn.2017.01.006. Epub 2017 Mar 20. Review.

PMID:
28554412
16.

Altered detrusor contractility in MPTP-treated common marmosets with bladder hyperreflexia.

Pritchard S, Jackson MJ, Hikima A, Lione L, Benham CD, Chaudhuri KR, Rose S, Jenner P, Iravani MM.

PLoS One. 2017 May 17;12(5):e0175797. doi: 10.1371/journal.pone.0175797. eCollection 2017.

17.

Apomorphine - pharmacological properties and clinical trials in Parkinson's disease.

Jenner P, Katzenschlager R.

Parkinsonism Relat Disord. 2016 Dec;33 Suppl 1:S13-S21. doi: 10.1016/j.parkreldis.2016.12.003. Epub 2016 Dec 13. Review.

PMID:
27979722
18.

Oral r-(-)-11-o-valeryl-n-n-propylnoraporphine reverses motor deficits in mptp-treated marmosets.

Lincoln L, Fisher R, Jackson MJ, Jenner P, Neumeyer J, Sromek AW, Lees AJ, Rose S.

Mov Disord. 2016 Sep;31(9):1381-8. doi: 10.1002/mds.26626. Epub 2016 May 2. Review.

PMID:
27133947
19.

Parkinson's Inside Out.

Stamford J, Scheller D, Jenner P.

J Parkinsons Dis. 2016;6(1):65-6. doi: 10.3233/JPD-160792. No abstract available.

20.

Non motor subtypes and Parkinson's disease.

Sauerbier A, Jenner P, Todorova A, Chaudhuri KR.

Parkinsonism Relat Disord. 2016 Jan;22 Suppl 1:S41-6. doi: 10.1016/j.parkreldis.2015.09.027. Epub 2015 Sep 11. Review.

PMID:
26459660
21.

The adenosine A2A receptor antagonist, istradefylline enhances anti-parkinsonian activity induced by combined treatment with low doses of L-DOPA and dopamine agonists in MPTP-treated common marmosets.

Uchida S, Soshiroda K, Okita E, Kawai-Uchida M, Mori A, Jenner P, Kanda T.

Eur J Pharmacol. 2015 Nov 5;766:25-30. doi: 10.1016/j.ejphar.2015.09.028. Epub 2015 Sep 28.

PMID:
26415982
22.

Treatment of the later stages of Parkinson's disease - pharmacological approaches now and in the future.

Jenner P.

Transl Neurodegener. 2015 Feb 12;4:3. doi: 10.1186/2047-9158-4-3. eCollection 2015. Review.

23.

Inhibition of i-NOS but not n-NOS protects rat primary cell cultures against MPP(+)-induced neuronal toxicity.

Brzozowski MJ, Jenner P, Rose S.

J Neural Transm (Vienna). 2015 Jun;122(6):779-88. doi: 10.1007/s00702-014-1334-8. Epub 2014 Dec 13.

PMID:
25503828
24.

The adenosine A2A receptor antagonist, istradefylline enhances the anti-parkinsonian activity of low doses of dopamine agonists in MPTP-treated common marmosets.

Uchida S, Soshiroda K, Okita E, Kawai-Uchida M, Mori A, Jenner P, Kanda T.

Eur J Pharmacol. 2015 Jan 15;747:160-5. doi: 10.1016/j.ejphar.2014.11.038. Epub 2014 Dec 11.

PMID:
25499739
25.

Multiple hemorrhagic infarcts in thrombotic thrombocytopenic purpura.

Alungal J, Abdulla MC, Koya JM, Jenner PF.

Neurol India. 2014 Sep-Oct;62(5):582-3. doi: 10.4103/0028-3886.144521. No abstract available.

26.
27.

Altered brain iron homeostasis and dopaminergic function in Restless Legs Syndrome (Willis-Ekbom Disease).

Earley CJ, Connor J, Garcia-Borreguero D, Jenner P, Winkelman J, Zee PC, Allen R.

Sleep Med. 2014 Nov;15(11):1288-301. doi: 10.1016/j.sleep.2014.05.009. Epub 2014 Jun 16. Review.

PMID:
25201131
28.

An overview of adenosine A2A receptor antagonists in Parkinson's disease.

Jenner P.

Int Rev Neurobiol. 2014;119:71-86. doi: 10.1016/B978-0-12-801022-8.00003-9. Review.

PMID:
25175961
29.

The H3 receptor agonist immepip does not affect l-dopa-induced abnormal involuntary movements in 6-OHDA-lesioned rats.

Papathanou M, Jenner P, Iravani M, Jackson M, Stockwell K, Strang I, Zeng BY, McCreary AC, Rose S.

Eur J Pharmacol. 2014 Oct 15;741:304-10. doi: 10.1016/j.ejphar.2014.08.004. Epub 2014 Aug 23.

PMID:
25160743
30.

A late appearance by the dopamine D-3 receptor.

Jenner P.

Mov Disord. 2014 Aug;29(9):1094-6. doi: 10.1002/mds.25958. Epub 2014 Jul 7. No abstract available.

PMID:
25044342
31.

Loss of locus coeruleus noradrenergic neurons alters the inflammatory response to LPS in substantia nigra but does not affect nigral cell loss.

Iravani MM, Sadeghian M, Rose S, Jenner P.

J Neural Transm (Vienna). 2014 Dec;121(12):1493-505. doi: 10.1007/s00702-014-1223-1. Epub 2014 Apr 30.

PMID:
24781752
32.

Non-motor Parkinson's: integral to motor Parkinson's, yet often neglected.

Todorova A, Jenner P, Ray Chaudhuri K.

Pract Neurol. 2014 Oct;14(5):310-22. doi: 10.1136/practneurol-2013-000741. Epub 2014 Apr 3. Review.

33.

Adenosine A₂A-receptor antagonist istradefylline enhances the motor response of L-DOPA without worsening dyskinesia in MPTP-treated common marmosets.

Uchida S, Tashiro T, Kawai-Uchida M, Mori A, Jenner P, Kanda T.

J Pharmacol Sci. 2014;124(4):480-5. Epub 2014 Mar 28.

34.

Antidepressant activity of the adenosine A2A receptor antagonist, istradefylline (KW-6002) on learned helplessness in rats.

Yamada K, Kobayashi M, Shiozaki S, Ohta T, Mori A, Jenner P, Kanda T.

Psychopharmacology (Berl). 2014 Jul;231(14):2839-49. doi: 10.1007/s00213-014-3454-0. Epub 2014 Feb 2.

PMID:
24488405
35.

Effect and mechanism of acupuncture on Alzheimer's disease.

Zeng BY, Salvage S, Jenner P.

Int Rev Neurobiol. 2013;111:181-95. doi: 10.1016/B978-0-12-411545-3.00009-2. Review.

PMID:
24215923
36.

Current development of acupuncture research in Parkinson's disease.

Zeng BY, Salvage S, Jenner P.

Int Rev Neurobiol. 2013;111:141-58. doi: 10.1016/B978-0-12-411545-3.00007-9. Review.

PMID:
24215921
37.

Antidepressant-like activity of the adenosine A(2A) receptor antagonist, istradefylline (KW-6002), in the forced swim test and the tail suspension test in rodents.

Yamada K, Kobayashi M, Mori A, Jenner P, Kanda T.

Pharmacol Biochem Behav. 2013 Dec;114-115:23-30. doi: 10.1016/j.pbb.2013.10.022. Epub 2013 Nov 4.

PMID:
24201052
38.

Proteomic analysis of striatum from MPTP-treated marmosets (Callithrix jacchus) with L-DOPA-induced dyskinesia of differing severity.

Hurley MJ, Jackson MJ, Smith LA, Rose S, Jenner P.

J Mol Neurosci. 2014 Feb;52(2):302-12. doi: 10.1007/s12031-013-0145-y. Epub 2013 Oct 23.

PMID:
24150990
39.

Design, synthesis and biological evaluation of peptide derivatives of L-dopa as anti-parkinsonian agents.

Zhou T, Hider RC, Jenner P, Campbell B, Hobbs CJ, Rose S, Jairaj M, Tayarani-Binazir KA, Syme A.

Bioorg Med Chem Lett. 2013 Oct 1;23(19):5279-82. doi: 10.1016/j.bmcl.2013.08.007. Epub 2013 Aug 11.

PMID:
23973169
40.
41.

Wearing off, dyskinesia, and the use of continuous drug delivery in Parkinson's disease.

Jenner P.

Neurol Clin. 2013 Aug;31(3 Suppl):S17-35. doi: 10.1016/j.ncl.2013.04.010. Epub 2013 Jun 14. Review.

42.

Parkinson's disease--the debate on the clinical phenomenology, aetiology, pathology and pathogenesis.

Jenner P, Morris HR, Robbins TW, Goedert M, Hardy J, Ben-Shlomo Y, Bolam P, Burn D, Hindle JV, Brooks D.

J Parkinsons Dis. 2013;3(1):1-11. doi: 10.3233/JPD-130175. Review.

43.

Effects of the adenosine A2A antagonist istradefylline on cognitive performance in rats with a 6-OHDA lesion in prefrontal cortex.

Kadowaki Horita T, Kobayashi M, Mori A, Jenner P, Kanda T.

Psychopharmacology (Berl). 2013 Dec;230(3):345-52. doi: 10.1007/s00213-013-3158-x. Epub 2013 Jun 10.

PMID:
23748382
44.

Expression of integrin and CD44 receptors recognising osteopontin in the normal and LPS-lesioned rat substantia nigra.

Ailane S, Long P, Jenner P, Rose S.

Eur J Neurosci. 2013 Aug;38(3):2468-76. doi: 10.1111/ejn.12231. Epub 2013 May 22.

PMID:
23692556
45.

A cup of coffee a day keeps dyskinesia away?

Jenner P.

Mov Disord. 2013 Mar;28(3):265-7. doi: 10.1002/mds.25409. Epub 2013 Feb 27. No abstract available.

PMID:
23447426
46.

Parkinson disease: from pathology to molecular disease mechanisms.

Dexter DT, Jenner P.

Free Radic Biol Med. 2013 Sep;62:132-144. doi: 10.1016/j.freeradbiomed.2013.01.018. Epub 2013 Feb 4.

PMID:
23380027
47.

New directions.

von Gersdorff H, Jenner P.

Synapse. 2013 Jan;67(1):1-3. doi: 10.1002/syn.21619. No abstract available.

PMID:
23192948
48.

Levodopa infusion does not decrease the onset of abnormal involuntary movements in parkinsonian rats.

Papathanou M, van der Laan R, Jenner P, Rose S, McCreary AC.

Mov Disord. 2013 Jul;28(8):1072-9. doi: 10.1002/mds.25218. Epub 2012 Nov 2.

PMID:
23125107
49.

Pathogenesis of Parkinson's disease.

Hirsch EC, Jenner P, Przedborski S.

Mov Disord. 2013 Jan;28(1):24-30. doi: 10.1002/mds.25032. Epub 2012 Aug 23. Review.

PMID:
22927094
50.

Differential toxicity of 6-hydroxydopamine in SH-SY5Y human neuroblastoma cells and rat brain mitochondria: protective role of catalase and superoxide dismutase.

Iglesias-González J, Sánchez-Iglesias S, Méndez-Álvarez E, Rose S, Hikima A, Jenner P, Soto-Otero R.

Neurochem Res. 2012 Oct;37(10):2150-60. doi: 10.1007/s11064-012-0838-6. Epub 2012 Jul 22.

PMID:
22821477

Supplemental Content

Loading ...
Support Center